HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Authors : Seda Kahraman, Mutlu Hızal, Özge Gümüşay, Gül Başaran, Mustafa Seyyar, Elif Sahin, Devrim Çabuk, Alper Yaşar, Vedat Bayoğlu, Ertuğrul Bayram, Semra Paydaş, Burcu Gülbağcı, İlhan Hacıbekiroğlu, Burçin Çakan Demirel, Arzu Yaren, Melike Özçelik, Funda Yılmaz, Mutlu Doğan, Nail Paksoy, Adnan Aydıner, Olcun Umit Unal, Murat Keser, Esra Aydın, Erkan Kayıkçıoğlu, Bülent Çetin, Serkan Menekşe, Engin Kut, Kerem Okutur, Naziyet Köse Baytemur, Umut Demirci, Cihan Erol, Fatih Selçuk Biricik, Deniz Işık, Özgecan Dülgar, Teoman Sakalar, Başak Oyan Uluç, Sena Ece Davarcı, Hacer Demir, Ömer Acar, Atike Pinar Erdoğan, Sibel Oyucu Orhan, Erdem Çubukçu, Dinçer Aydın, Yusuf Karakas, Hakan Yücel, Gülhan Özkanlı, Eda Eylemer Mocan, Denizcan Güven, Orhan Önder Eren, Burak Bilgin, Nurhan Önal Kalkan, Yakup İriağaç, Muhammed Muhiddin Er, Nilgün Yıldırım, Merve Keskinkılıç, Özlem Özdemir, Veli Sunar, Nazım Serdar Turhal, Berna Bozkurt Duman, Muhammed Bülent Akıncı, Musa Barış Aykan, Müge Karaoğlanoğlu, Özlem Doğan, Ali İnal, Mehmet Ali Şendur

Pages : 255-262

Doi:10.18663/tjcl.1639022

View : 81 | Download : 67

Publication Date : 2025-06-30

Article Type : Research Paper

Abstract :Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.
Keywords : CDK4/6 inhibitörleri, metastatik meme kanseri, HER2-düşük ekspresyonu

ORIGINAL ARTICLE URL